Breaking News Instant updates and real-time market news.

GILD

Gilead

$75.29

0.96 (1.29%)

10:21
04/13/18
04/13
10:21
04/13/18
10:21

Gilead presents data from proof-of-concept study in NASH patients

Gilead Sciences presented today data from a proof-of-concept study of investigational combination therapies for patients with advanced fibrosis due to nonalcoholic steatohepatitis, combining the apoptosis signal-regulating kinase 1 inhibitor selonsertib with either the Acetyl-CoA carboxylase inhibitor GS-0976 or the selective, non-steroidal Farnesoid X receptor (FXR) agonist GS-9674. The data were presented at The International Liver Congress 2018 in Paris. More than 25 additional Gilead abstracts on NASH and other fibrotic liver diseases are also being presented, including data from predictive modeling studies using noninvasive tests for the diagnosis and monitoring of NASH that aim to reduce the need for liver biopsy. The proof-of-concept study included 70 patients. All patients in the study were diagnosed with NASH and liver fibrosis stages F2 to F3 based on biopsy, or by magnetic resonance elastography and MRI proton density fat fraction. The greatest changes observed after 12 weeks of treatment in the study were decreases in liver fat content, which occurred in regimens containing GS-0976. Improvements in liver biochemistry and/or markers of fibrosis were also observed across both combination arms of the study compared to baseline, the company said. In patients treated with selonsertib plus GS-0976, kinetic labeling revealed the largest reduction in the fractional synthesis rate of lumican, a marker of fibrogenesis. Similar rates of adverse events were observed between patients treated with single-agent and combination therapies. No patient discontinued treatment prematurely. "These encouraging results suggest that combination therapy with selonsertib and either GS-0976 or GS-9674 warrants further exploration in longer-term studies in patients with NASH and F3 and F4 fibrosis," said Stephen Harrison, MD, presenting author and Visiting Professor of Hepatology at the Radcliffe Department of Medicine, University of Oxford, UK. "Patients with advanced fibrosis due to NASH urgently need effective therapeutic options because they may face more serious health risks, including development of complications of end-stage liver disease, liver cancer and the need for liver transplantation. Combination therapy may be a way forward to achieving greater benefit for this patient population."

  • 13

    Apr

  • 20

    Apr

  • 18

    May

GILD Gilead
$75.29

0.96 (1.29%)

02/23/18
FBCO
02/23/18
NO CHANGE
Target $80
FBCO
Neutral
Gilead's near-term launches 'intact' after CCO retirement, says Credit Suisse
Credit Suisse analyst Alethia Young told investors in a research note that she is not concerned about the departure of Gilead Sciences' Chief Commercial Officer Jim Myers after speaking with the company's management. She said that she is "confident" in her estimates around the recent launch for Bictarvy and Yescarta, noting that Myers' departure "has nothing to do" with a performance issue or disagreement, adding that Myers had taken a leave of absence earlier in the year due to family matters. She also noted that the company has had turnover in the CCO role with "limited' disruption. Young has a Neutral rating on Gilead shares.
03/06/18
LEHM
03/06/18
NO CHANGE
Target $95
LEHM
Overweight
Gilead target raised to $95 on favorable doctor survey at Barclays
Barclays analyst Geoff Meacham raised his price target for Gilead Sciences to $95 from $90 after his doctor surgery to assess the outlook for the company's HIV franchise was more favorable than expected. The survey shows stronger than expected support for Biktarvy, Meacham tells investors in a research note. Gilead's HIV franchise will "be the bridge until the next leg of growth from CAR-T and the pipeline kicks in," the analyst tells investors in a research note. He keeps an Overweight rating on Gilead.
03/07/18
LEHM
03/07/18
NO CHANGE
Target $59
LEHM
Overweight
Crispr Therapeutics price target raised to $59 from $29 at Barclays
Barclays analyst Gena Wang raised her price target for Crispr Therapeutics (CRSP) to $59 citing the company's technology platform and pipeline value. Several recent events, including the acquisitions of Kite and Juno and Sangamo (SGMO) collaboration with Gilead (GILD), validated the value of cell therapy and the potential of gene-editing technologies to serve as a powerful tool in developing next-generation products, Wang tells investors in a research note. She sees "strong upside potential" in Crispr shares and keeps an Overweight rating on the name.
03/21/18
MSCO
03/21/18
NO CHANGE
Target $209
MSCO
Equal Weight
Bluebird Bio price target to $209 from $152 at Morgan Stanley
Morgan Stanley analyst Matthew Harrison raised his price target on Bluebird Bio (BLUE) to $209 from $152, stating that he now expects BCMA therapies to take 50% of the third line market by 2030 and noting that bb2121 has 50% market share there. The new assumptions increase his peak sales forecast to about $2.6B from about $1B, he pointed out. However, Harrison keeps an Equal Weight rating on Bluebird, stating that he would expect new data to be available at ASCO in June, but would also expect to see competitor data potentially from Celgene's (CELG) Juno, Gilead's (GILD) Kite, Johnson & Johnson's (JNJ) Nanjing Legend and others.

TODAY'S FREE FLY STORIES

ITCI

Intra-Cellular

$20.81

0.19 (0.92%)

07:14
07/23/18
07/23
07:14
07/23/18
07:14
Hot Stocks
Intra-Cellular announces publication highlighting ITI-214 »

Intra-Cellular Therapies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RYB

RYB Education

$21.21

-0.33 (-1.53%)

07:14
07/23/18
07/23
07:14
07/23/18
07:14
Initiation
RYB Education initiated  »

RYB Education initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCLP

Hi-Crush Partners

$10.85

-0.575 (-5.03%)

07:13
07/23/18
07/23
07:13
07/23/18
07:13
Hot Stocks
Hi-Crush Partners raises quarterly distribution to 75c per unit »

Hi-Crush Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

ACRE

Ares Commercial

$13.99

-0.05 (-0.36%)

07:13
07/23/18
07/23
07:13
07/23/18
07:13
Initiation
Ares Commercial initiated  »

Ares Commercial initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

BPL

Buckeye Partners

$33.10

0.01 (0.03%)

07:13
07/23/18
07/23
07:13
07/23/18
07:13
Downgrade
Buckeye Partners rating change  »

Buckeye Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

BV

BrightView

$21.95

0.14 (0.64%)

07:11
07/23/18
07/23
07:11
07/23/18
07:11
Initiation
BrightView initiated  »

BrightView initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCLP

Hi-Crush Partners

$10.85

-0.575 (-5.03%)

07:11
07/23/18
07/23
07:11
07/23/18
07:11
Hot Stocks
Hi-Crush Partners acquires FB Industries »

Hi-Crush Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

ALNY

Alnylam

$105.86

-0.36 (-0.34%)

07:11
07/23/18
07/23
07:11
07/23/18
07:11
Hot Stocks
Alnylam announces presentations from APOLLO Phase 3 study of patisiran at PNS »

Alnylam announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Aug

MPWR

Monolithic Power

$140.71

-1.05 (-0.74%)

07:10
07/23/18
07/23
07:10
07/23/18
07:10
Conference/Events
Monolithic Power management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 26

    Jul

  • 30

    Jul

  • 14

    Aug

HTHT

China Lodging

$41.02

0.76 (1.89%)

07:09
07/23/18
07/23
07:09
07/23/18
07:09
Conference/Events
China Lodging management to meet with Benchmark »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 27

    Jul

  • 22

    Aug

IRWD

Ironwood

$20.03

-0.035 (-0.17%)

07:09
07/23/18
07/23
07:09
07/23/18
07:09
Initiation
Ironwood initiated  »

Ironwood initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLIR

Flir Systems

$53.96

-0.55 (-1.01%)

07:09
07/23/18
07/23
07:09
07/23/18
07:09
Conference/Events
Flir Systems management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 26

    Jul

ARCT

Arcturus Therapeutics

$8.40

-0.09 (-1.06%)

07:09
07/23/18
07/23
07:09
07/23/18
07:09
Hot Stocks
Arcturus achieves program milestones, refines agreement with CF Foundation »

Arcturus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RETA

Reata Pharmaceuticals

$46.43

(0.00%)

07:08
07/23/18
07/23
07:08
07/23/18
07:08
Conference/Events
Reata Pharmaceuticals to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

LAD

Lithia Motors

$95.34

-0.85 (-0.88%)

07:07
07/23/18
07/23
07:07
07/23/18
07:07
Hot Stocks
Lithia Motors announces Erik Lewis as CHRO »

Lithia Motors announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

KALA

Kala Pharmaceuticals

$12.28

-0.19 (-1.52%)

07:07
07/23/18
07/23
07:07
07/23/18
07:07
Initiation
Kala Pharmaceuticals initiated  »

Kala Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 24

    Aug

JMEI

Jumei

$2.07

-0.05 (-2.36%)

07:06
07/23/18
07/23
07:06
07/23/18
07:06
Hot Stocks
Jumei announces $27.6M in share repurchase since April »

Jumei announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLRN

Acceleron

$46.57

0.47 (1.02%)

07:05
07/23/18
07/23
07:05
07/23/18
07:05
Hot Stocks
Acceleron reports preliminary results from Part 1 of ACE-083 Phase 2 trial »

Acceleron Pharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NNVC

NanoViricides

$0.41

-0.002 (-0.49%)

, OHRP

Ohr Pharmaceutical

$0.20

-0.0019 (-0.94%)

07:05
07/23/18
07/23
07:05
07/23/18
07:05
Hot Stocks
NanoViricides names Dr. Irach Taraporewala as new CEO »

NanoViricides (NNVC) is…

NNVC

NanoViricides

$0.41

-0.002 (-0.49%)

OHRP

Ohr Pharmaceutical

$0.20

-0.0019 (-0.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:05
07/23/18
07/23
07:05
07/23/18
07:05
General news
Oil Action: Front-month WTI prices are up 1.2% »

Oil Action: Front-month…

WVE

Wave Life Sciences

$39.05

1.15 (3.03%)

07:04
07/23/18
07/23
07:04
07/23/18
07:04
Initiation
Wave Life Sciences initiated  »

Wave Life Sciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDR

McDermott

$17.63

-0.09 (-0.51%)

07:04
07/23/18
07/23
07:04
07/23/18
07:04
Hot Stocks
McDermott awarded EPC contract in Saudi Arabia »

McDermott International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

AGTC

Applied Genetic

$4.05

-0.15 (-3.57%)

, BIIB

Biogen

$358.72

0.55 (0.15%)

07:04
07/23/18
07/23
07:04
07/23/18
07:04
Hot Stocks
Applied Genetic treats first patient of second cohort in clinical XLRP study »

Applied Genetic (AGTC)…

AGTC

Applied Genetic

$4.05

-0.15 (-3.57%)

BIIB

Biogen

$358.72

0.55 (0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 30

    Jul

  • 31

    Jul

OPB

Opus Bank

$29.65

-0.2 (-0.67%)

07:04
07/23/18
07/23
07:04
07/23/18
07:04
Earnings
Opus Bank reports Q2 EPS 40c, consensus 39c »

Net income of $15.5M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 07

    Nov

AMZN

Amazon.com

$1,813.84

0.99 (0.05%)

07:03
07/23/18
07/23
07:03
07/23/18
07:03
Recommendations
Amazon.com analyst commentary  »

Wedbush expects Amazon to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 16

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.